Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenishaw Regulatory News (RSW)

Share Price Information for Renishaw (RSW)

Share Price is delayed by 15 minutes
Get Live Data
5,245.00    -145.00 (-2.69%)
Bid:
5,240.00
Ask:
5,250.00
Spread: 10.00 (0.191%)
Market Cap: £3.81b
RSW Live PriceLast checked at - London Stock Exchange

Intraday Renishaw Share Chart

Interim Management Statement

17 May 2011 07:00

RNS Number : 6863G
Renishaw PLC
17 May 2011
 



Renishaw plc

Interim management statement

 

This Interim management statement contains unaudited information and covers the period 1st January 2011 to 16th May 2011.

 

Trading activity

We are pleased to report that the strong performance of the Group reported in our interim results has continued throughout the third quarter of this financial year.

 

Revenue for the third quarter was £75.6m, 60% ahead of the comparable period last year, helped by particularly strong revenue of £32.0m in March 2011. The cumulative revenue for the 9 months to 31st March 2011 of £204.9m (approximately 95% of which were sales to overseas customers) was 69% ahead of the £121.1m for the comparable period last year. Metrology revenue for the 9 months was £190.6m, compared with £108.4m last year, an increase of 76% and Healthcare revenue was £14.3m, compared with £12.7m last year, an increase of 13%.

 

Profit before tax for the 9 months to 31st March 2011 amounted to £60.3m, compared with £15.5m last year.

 

Significant growth has been experienced in the Far East, particularly in China, and we have seen good growth in all regions, compared with the comparable period last year.

 

In March 2011 Japan was affected by a severe earthquake. The impact on Renishaw's operations has been minimal. Our Tokyo office was closed for a short time as result of transport issues in the city, but suffered no damage. Neither sales to customers nor Renishaw's own supply chain has been significantly affected.

 

The Group has focused on developing the organisation to meet the rapid growth in customer demand and has, since 1st July 2010, taken on 285 new personnel to support this growth, as well as to continue the development of new products and processes to maintain this growth into the future. Headcount at the end of March 2011 was 2,384, compared with 2,099 at the start of the financial year and there are currently 293 vacancies throughout the Group, 235 in the UK and 58 overseas.

 

The Group continues to invest significantly in research and development programmes in both the Metrology and Healthcare sectors. A number of new products have been launched since our last report. In our Metrology business, Equator™, a radical new alternative to traditional dedicated gauging, was launched in February 2011 as well as RoLin™, a component level encoder. In our Healthcare business, Renishaw Diagnostics Limited ("RDL") has released the RenDx™ RUO multiplex assay system, a research only machine, which allows precious research samples to be screened for 10 or more targets from a single sample. RDL is preparing to apply for approval of the RenDx™ multiplex assay system as a medical device.

 

Acquisitions

As noted in our interim results, the Group increased its shareholding in Measurement Devices Limited in January 2011. Also, during the period, the Group acquired the remaining minority shareholding in PulseTeq Limited.

 

In April 2011, the Group acquired a 100% shareholding in MTT Investments Limited ("MTT"), a business that designs, develops and manufactures additive manufacturing and rapid prototyping systems, including selective laser melting, metal casting, and vacuum casting machines and processes. Based in Stone, Staffordshire, in the UK, MTT has 35 employees, with subsidiaries in the USA and Italy, and a branch office in France. MTT's selective laser melting equipment currently has its main markets in aerospace and medical devices, but also has potential for use in other sectors. Its products are complementary to Renishaw's existing technologies and business.

 

Financial position

The Group has invested substantially in working capital since the start of the financial year, including an increase in inventories of £11.2m over the 9 months, to ensure meeting customer demands, as well as investing £11.4m in capital expenditure, mainly in expanding our manufacturing facilities. The Group maintains a solid balance sheet, with net cash balances of £35.3m at 31st March 2011, compared with £31.1m at 30th June 2010.

 

Outlook

Current activity levels remain strong and broadly in line with the run-rate for the year to date. On this basis, the Board looks forward to record results and anticipates that pre-tax profits for the year will be ahead of current market expectations, which have a consensus of around £75m* for pre-tax profits.

 

Sir David McMurtry CBE, RDI, FREng, CEng, FIMechE

Chairman and Chief Executive

 

17th May 2011

 

Renishaw plc

Registered office New Mills, Wotton-under-Edge, Gloucestershire, GL12 8JR

Registered number 1106260

Telephone number 01453 524524

Website www.renishaw.com

 

* based on Reuters consensus estimates as of 13th May 2011

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSAFMATMBJBBJB
Date   Source Headline
22nd Sep 20203:11 pmRNSReplacement Director/PDMR Shareholding
22nd Sep 20202:19 pmRNSDirector/PDMR Shareholding
8th Sep 20204:35 pmRNSDirector/PDMR Shareholding
1st Sep 20207:00 amRNSAnnual Financial Report
27th Aug 20207:00 amRNSDirector/PDMR Shareholding
17th Aug 20203:15 pmRNSDirector/PDMR Shareholding
13th Aug 20207:00 amRNSFinal Results
6th Aug 202010:00 amRNSNotice of Results
17th Jul 20208:06 amRNSTrading Statement
26th Jun 20201:08 pmRNSDirector/PDMR Shareholding
24th Jun 20203:35 pmRNSDirector/PDMR Shareholding
22nd Jun 20204:17 pmRNSDirector/PDMR Shareholding
10th Jun 20202:00 pmRNSDirector/PDMR Shareholding
5th Jun 20207:00 amRNS2020 Final Dividend
12th May 20207:00 amRNSTrading Statement
4th May 202012:00 pmRNSDisclosure of Rights Attached to Equity Shares
2nd Apr 20204:30 pmRNSStatement re 2019 AGM resolution votes
25th Mar 20204:28 pmRNSStatement re Interim dividend
6th Mar 20209:36 amRNSDirector/PDMR Shareholding
27th Feb 20204:47 pmRNSStatement re Interim dividend
30th Jan 20207:00 amRNSHalf-year Report
29th Jan 20205:45 pmRNSChange in Director's Responsibilities
20th Jan 202012:00 pmRNSNotice of Half-year Results
17th Jan 20209:47 amRNSHolding(s) in Company
24th Oct 20193:37 pmRNSResult of AGM
15th Oct 20197:00 amRNSTrading Statement
30th Aug 20193:00 pmRNSPurchase of Shares by Profit Share Trust
21st Aug 20197:00 amRNSAnnual Financial Report
1st Aug 20197:00 amRNSFinal Results
16th Jul 20193:00 pmRNSNotice of Results
25th Jun 20197:00 amRNSDirectorate Change
14th May 201910:00 amRNSDirector Declaration
14th May 20197:00 amRNSTrading Statement
27th Mar 201911:36 amRNSDirector/PDMR Shareholding
22nd Mar 20199:48 amRNSDirector/PDMR Shareholding
21st Mar 20197:00 amRNSTrading Statement
12th Mar 20194:00 pmRNSNotice of Investor Day
31st Jan 20197:00 amRNSHalf-year Report
15th Jan 20193:00 pmRNSNotice of Half-year Results
19th Dec 201810:07 amRNSDirector/PDMR Shareholding
29th Oct 20189:56 amRNSDirector/PDMR Shareholding
23rd Oct 201810:02 amRNSDirector/PDMR Shareholding
22nd Oct 201810:43 amRNSDirector/PDMR Shareholding
18th Oct 20184:02 pmRNSResult of AGM
18th Oct 20187:00 amRNSTrading Statement
23rd Aug 20182:00 pmRNSPurchase of Shares by Profit Share Trust
21st Aug 20187:00 amRNSAnnual Financial Report
3rd Aug 201812:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20183:00 pmRNSDirector Declaration
26th Jul 20187:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.